

10-17-06

AF

PATENT

Customer No. 22,852

Attorney Docket No. 03495.194-01

Express Mail Label No.: EV 799294695 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Penelope MAVROMARA et al.) Group Art Unit: 1636
Application No.: 10/664,038) Examiner: James S. Ketter
Filed: September 17, 2003))
For: NUCLEIC ACIDS AND NEW POLYPEPTIDES ASSOCIATED WITH AND/OR OVERLAPPING WITH HEPATITIS C VIRUS CORE GENE PRODUCTS	Confirmation No.: 3906)))

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EV 799294695 USOctober 16, 2006USPS Express Mail Label NumberDate of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherleen Goodlette

Attachments:

- 1. Amendment After Final (8 pages)
- 2. Post Card to Acknowledge Receipt



RESPONSE UNDER 37 C.F.R. § 1.116 EXPEDITED PROCEDURE REQUESTED EXAMINING GROUP 1636

PATENT

Attorney Docket No. 03495.0194-01

Express Mail Label No.: EV 799294695 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Penelope MAVROMARA et al.) Group Art Unit: 1636
Application No.: 10/664,038) Examiner: James S. Ketter
Filed: September 17, 2003))
For: NUCLEIC ACIDS AND NEW POLYPEPTIDES ASSOCIATED WITH AND/OR OVERLAPPING WITH HEPATITIS C VIRUS CORE GENE PRODUCTS	Confirmation No.: 3906)))
Mail Stop AF	

Mail Stop AF P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

AMENDMENT AFTER FINAL

In reply to the Final Office Action mailed July 14, 2006, and pursuant to 37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

Amendments to the Specification are included in this paper at page 2.

Amendments to the Claims are reflected in the listing of claims in this paper, beginning on page 3.

Remarks/Arguments follow the amendment sections of this paper, beginning on page 5.